| 标题： | 131I治疗儿童及青少年格雷夫斯甲亢中国专家共识 |
| title： | Chinese Expert Consensus on 131I therapy for Graves’ hyperthyroidism in children and adolescents |
| 版本： | 原创版 |
| version： | Original |
| 分类： | 专家共识 |
| classification： | Experts consensus |
| 领域： | 诊疗 |
| field： | Diagnosis and Treatment |
| 国家和地区： | 中国 |
| Country and region： | China |
| 指南使用者： | 这个共识面向从事甲亢疾病诊治相关工作的执业医师、护士、技术人员及相关科研工作人员。 |
| Guide users： | This consensus will be helpful for practitioners, nurses, technicians and relevant scientific research workers engaged in hyperthyroidism related work. |
| 证据分级方法： | 采用GRADE方法评价各临床问题证据体的质量，将证据质量分为高、中、低、极低4个等级。RCT起始评价为高质量证据，观察性研究起始评价为低质量证据。在证据分级过程中，局限性、不精确性、不一致性、间接性以及发表偏倚等5个为降级因素，而效应量大、剂量反应关系以及可能的混杂因素等3个为升级因素。 |
| Evidence grading method： | We will assess the certainty of evidence using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) system and classify evidence as to be high, moderate, low, or very low certainty.The initial evaluation of RCT was high-quality evidence, and the initial evaluation of observational study was low-quality evidence. In the process of evidence grading, five factors such as limitation, imprecision, inconsistency, indirectness and publication bias were downgraded, while three factors such as large amount of effect, dose response relationship and possible confounding factors were upgraded. |
| 制定单位： | 上海市甲状腺疾病研究中心 同济大学附属第十人民医院 |
| Formulating unit： | Shanghai Thyroid Disease Research Center; The tenth People's Hospital affiliated to Tongji University |
| 注册时间： | 2022-09-21 |
| Registration time： | |
| 注册编号： | PREPARE-2022CN613 |
| Registration number： | |
| 指南制订的目的： | 131I治疗作为甲亢的一种常规治疗方式，已应用于儿童及青少年格雷夫斯甲亢（Graves′ hyperthyroidism，GH）患者，但由于儿童及青少年群体的特殊性，出于对使用131I治疗后继发恶性肿瘤的担忧等，使得大多数国内外专家对使用131I治疗儿童及青少年GH的选择相对谨慎。鉴于131I治疗儿童及青少年GH新证据的不断涌现, 亟需采用循证医学方法构建出我国文化背景下的131I治疗儿童及青少年GH临床诊疗指南或专家共识，以指导和规范我国131I治疗儿童及青少年GH临床诊疗决策，为儿童及青少年GH患者的健康进行保驾护航。 |
| Purpose of the guideline： | 131I therapy, as a routine treatment for hyperthyroidism, has been widely used in children and adolescents with Graves′ hyperthyroidism(GH）. However, due to the particularity of children and adolescents, most experts at home and abroad are relatively cautious about using 131I to treat children and adolescents with GH due to their concerns about secondary malignant tumors after 131I therapy. In view of the continuous emergence of new evidence on 131I treatment of GH for children and adolescents, it is urgent to adopt evidence-based medicine to build a clinical diagnosis and treatment guide or expert consensus on 131I treatment of GH for children and adolescents under the cultural background of China, so as to guide and standardize the clinical diagnosis and treatment decisions on 131I treatment of GH for children and adolescents in China, and to protect the health of children and adolescents with GH. |
